Table of Contents
International Scholarly Research Notices
Volume 2017 (2017), Article ID 8404378, 6 pages
https://doi.org/10.1155/2017/8404378
Clinical Study

Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex

1Paediatric Neurology, University College London and University Hospitals Bristol, London, UK
2Paediatric Neurology, University Hospitals Bristol, Bristol, UK
3Dermatology, University Hospital of North Durham, Durham, UK
4Paediatric Neurosciences, University College London, London, UK

Correspondence should be addressed to S. Amin

Received 8 August 2017; Accepted 18 October 2017; Published 15 November 2017

Academic Editor: José María Huerta

Copyright © 2017 S. Amin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. P. Osborne, A. Fryer, and D. Webb, “Epidemiology of tuberous sclerosis,” Annals of the New York Academy of Sciences, vol. 615, pp. 125–127, 1991. View at Publisher · View at Google Scholar · View at Scopus
  2. M. van Slegtenhorst, R. de Hoogt, C. Hermans et al., “Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34,” Science, vol. 277, no. 5327, pp. 805–808, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. The European Chromosome 16 Tuberous Sclerosis Consortium, “Identification and characterization of the tuberous sclerosis gene on chromosome 16,” Cell, vol. 75, no. 7, pp. 1305–1315, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Nellist, M. A. Van Slegtenhorst, M. Goedbloed, A. M. W. Van Den Ouweland, D. J. J. Halley, and P. Van Der Sluijs, “Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin,” The Journal of Biological Chemistry, vol. 274, no. 50, pp. 35647–35652, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. A. R. Tee, D. C. Fingar, B. D. Manning, D. J. Kwiatkowski, L. C. Cantley, and J. Blenis, “Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 99, no. 21, pp. 13571–13576, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. Skin (Dermatological) Manifestations in TSC, Tuberous Sclerosis Alliance, http://tsalliance.org/pages.aspx?content=601.
  7. M. K. Koenig, A. A. Hebert, J. Roberson et al., “Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin,” Drugs in R&D, vol. 12, no. 3, pp. 121–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Easton and P. J. Houghton, “mTOR and cancer therapy,” Oncogene, vol. 25, no. 48, pp. 6436–6446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Vézina, A. Kudelski, and S. N. Sehgal, “Rapamycin (AY 22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle,” The Journal of Antibiotics, vol. 28, no. 10, pp. 721–726, 1975. View at Publisher · View at Google Scholar · View at Scopus
  10. D. R. Plas and G. Thomas, “Tubers and tumors: rapamycin therapy for benign and malignant tumors,” Current Opinion in Cell Biology, vol. 21, no. 2, pp. 230–236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Bissler, F. X. McCormack, L. R. Young et al., “Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis,” The New England Journal of Medicine, vol. 358, no. 2, pp. 140–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. D. A. Krueger, M. M. Care, K. Holland et al., “Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1801–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. S. Foster, L. J. Bint, and A. R. Halbert, “Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patients,” Australasian Journal of Dermatology, vol. 53, no. 1, pp. 52–56, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Northrup and D. A. Krueger, “Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference,” Pediatric Neurology, vol. 49, no. 4, pp. 243–254, 2013. View at Publisher · View at Google Scholar
  15. F. J. O'Callaghan, M. J. Noakes, C. N. Martyn, and J. P. Osborne, “An epidemiological study of renal pathology in tuberous sclerosis complex,” BJU International, vol. 94, no. 6, pp. 853–857, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Salido, G. Garnacho-Saucedo, I. Cuevas-Asencio et al., “Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis—associated facial angiofibroma,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 10, pp. 1315–1318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Upton, C. Eiser, I. Cheung et al., “Measurement properties of the UK-English version of the Pediatric Quality of Life Inventory™ 4.0 (PedsQL™) generic core scales,” Health and Quality of Life Outcomes, vol. 3, article no. 22, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Burholt and P. Nash, “Short Form 36 (SF-36) Health Survey Questionnaire: Normative data for Wales,” Journal of Public Health, vol. 33, no. 4, pp. 587–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Tanaka, M. Wataya-Kaneda, A. Nakamura, S. Matsumoto, and I. Katayama, “First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex,” British Journal of Dermatology, vol. 169, no. 6, pp. 1314–1318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Tu, R. S. Foster, L. J. Bint, and A. R. Halbert, “Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions,” Australasian Journal of Dermatology, vol. 55, no. 1, pp. 63–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Lahti, H. Kopola, A. Harila, R. MyllylÄ, and M. Hannuksela, “Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter,” Archives of Dermatological Research, vol. 285, no. 5, pp. 278–282, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. J. A. Dake, J. H. Price, and S. K. Telljohann, “The nature and extent of bullying at school,” Journal of School Health, vol. 73, no. 5, pp. 173–180, 2003. View at Publisher · View at Google Scholar · View at Scopus